Longeveron (NASDAQ:LGVN) Stock Rating Cut to “Sell” at Wall Street Zen

Longeveron (NASDAQ:LGVN) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings downgraded Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $80.00.

Longeveron Stock Down 16.2%

Longeveron stock opened at $2.49 on Friday. The company has a market capitalization of $7.94 million, a PE ratio of -0.31 and a beta of -0.09. Longeveron has a 12-month low of $1.31 and a 12-month high of $12.30. The firm’s fifty day moving average is $2.92 and its 200 day moving average is $6.44.

Longeveron (NASDAQ:LGVN) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($1.91) EPS for the quarter, missing analysts’ consensus estimates of ($1.70) by ($0.21). Longeveron had a negative return on equity of 209.21% and a negative net margin of 1,921.72%. The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.80 million. Sell-side analysts expect that Longeveron will post -7.20 EPS for the current fiscal year.

Institutional Trading of Longeveron

A hedge fund recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC bought a new stake in Longeveron Inc. (NASDAQ:LGVN) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned approximately 0.86% of Longeveron as of its most recent SEC filing. Institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes. Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.